Vanguard Global Advisers
SLDB icon

Vanguard Global Advisers’s Solid Biosciences SLDB Stock Holding History

Vanguard Global Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
58,591
+22,189
+61% +$168K ﹤0.01% 2029
2026
Q1 		$262K Buy
+36,402
New +$234K ﹤0.01% 2310

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's SLDB Position: Q2 2026 in Review

Vanguard Global Advisers increased its Solid Biosciences (SLDB) stake by 61% in Q2 2026, buying an estimated $168K and bringing the position to 58,591 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Vanguard Global Advisers first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Vanguard Global Advisers held 58,591 shares of Solid Biosciences worth $585K as of Q2 2026.
  • Vanguard Global Advisers bought 22,189 Solid Biosciences shares in Q2 2026, an estimated $168K.
  • Solid Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2029 holding.
  • Vanguard Global Advisers first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.